Cytarabine
9,804 views
Oncology Pharm
- Bleomycin
- Dactinomycin, Actinomycin D
- Doxorubicin, Daunorubicin
- Azathioprine, 6-MP
- Cladribine
- Cytarabine
- Busulfan
- Cyclophosphamide, Ifosfamide
- Nitrosoureas
- Paclitaxel
- Vincristine, Vinblastine
- Cisplatin, Carboplatin, Oxaliplatin
- Etoposide, Teniposide
- Irinotecan, Topotecan
- Bevacizumab
- Erlotinib
- Cetuximab, Panitumumab
- Imatinib, Dasatinib
- Rituximab
- Bortezomib, Carfilzomib
- Trastuzumab
- Dabrafenib, Vemurafenib
- Raloxifene and Tamoxifen
- Hydroxyurea
- Procarbazine
Summary
Cytarabine is a pyrimidine analog and chemotherapeutic agent that kills rapidly dividing cells by causing DNA chain termination and inhibiting DNA polymerase during the S phase of the cell cycle. It’s clinical uses include treatment of leukemias and lymphomas, but its side effects include myelosuppression, pancytopenia, and megaloblastic anemia.
Key Points
- Cytarabine
- Same mechanism as gemcitabine
- Mechanism
- Pyrimidine analog
- Causes DNA chain termination
- At higher concentrations, inhibits DNA polymerase
- Causes DNA chain termination
- Pyrimidine analog
- Adverse Effects
- Megaloblastic anemia
- Any drug that inhibits DNA production may lead to megaloblastic change
- Myelosuppression / pancytopenia
- Megaloblastic anemia
- Clinical Use
- Leukemias (AML, ALL), lymphomas (high grade non-Hodgkins lymphoma)